Eduard Batlle is ICREA Senior Research Professor, Head of the Colorectal Cancer laboratory and Coordinator of the Oncology program at the Institute for Research in Biomedicine (IRB Barcelona, Spain), since 2004.
1993 BSc. Universitat de Barcelona.
1994-1999 PhD fellow at Institut Municipal de Investigació Mèdica (IMIM).
1999 Associate professor in Biochemistry –Life Sciences at the Pompeu Fabra University, Barcelona.
1999- 2000 PostDoctoral Fellow at Miguel Beato’s group- Institut für Molekularbiologie und Tumorforschung, Marburg. Germany.
2000-2004: PostDoctoral Fellow at Hans Clevers Lab, Netherlands Institute for Developmental Biology, Utrecht, NL.
ERC-Proof of Concept (2018)
ERC-Advance Grant (2013)
ERC-Proof of Concept (2014)
ERC- Starting Grant (2007)
Medalla de la Fundación Internacional Olof Palme (2018)
Fundación Francisco Cobos Award (2017)
Fundación Carmen y Severo Ochoa Award (2016)
Lilly Foundation National Award (2016)
XI Premio Ciencias de la Salud Fundación Caja Rural de Granada (2015)
EACR-Pezcoller Award (2014)
Josef Steiner Cancer Research Award (2013)
Drs. Diz Pintado Award (2013)
Banc de Sabadell Award for Biomedical Research (2010)
Debiopharm Life science award (2006)
The research activity of the Batlle Lab is focused on the characterization of the mechanisms that drive colorectal cancer. The group pioneered research connecting the biology of intestinal stem cells with that of their tumor counterparts, the so-called cancer stem cells (Batlle et al., Cell 2002; Merlos-Suarez et al., Cell Stem Cell 2011, Jung et al., Nat Med 2011; Whissell et al., Nat Cell Biol 2014; Barriga et al., Cell Stem Cell 2017). More recently, we have developed a strong interest in the mechanisms that drive metastatic dissemination of the disease, which has led to the discovery of a critical role of the tumor microenvironment on metastasis formation. A TGF-beta altered stroma segregates with poor prognosis and disease relapse in colorectal cancer (Calon et al., Cancer Cell 2012; Calon et al., Nature Genetics 2015). Moreover we have described how TGF-beta drives immune evasion and resistance to checkpoint therapies in CRC, providing a rationale for new therapy combinations for the treatment of metastatic CRC which are soon going to be tested in clinical trials (Tauriello et al., Nature 2018). In addition, these discoveries represent the basis for translational projects aiming to improve diagnosis and treatment of CRC patients. Our previous works on EPH signaling founded the field of research on EPHs and ephrins in cancer (Batlle et al., Nature 2005; Cortina et al., Nature Genetics 2007; Solanas et al., Nat Cell Biol 2011). In addition, we originally discovered the transcription factor Snail as a suppressor of E-cadherin expression in tumor cells, a discovery that founded the research field on Epithelial to Mesenchymal Transition (EMT) in cancer (Batlle et al, Nat Cell Biol 2000).